252 related articles for article (PubMed ID: 16586089)
1. Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats.
Zhang HT; Zhao Y; Huang Y; Deng C; Hopper AT; De Vivo M; Rose GM; O'Donnell JM
Psychopharmacology (Berl); 2006 Jun; 186(2):209-17. PubMed ID: 16586089
[TBL] [Abstract][Full Text] [Related]
2. Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]piclamilast and [3H]rolipram.
Zhao Y; Zhang HT; O'Donnell JM
J Pharmacol Exp Ther; 2003 May; 305(2):565-72. PubMed ID: 12704225
[TBL] [Abstract][Full Text] [Related]
3. Interaction between the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDE inhibitor rolipram in rats.
Zhang HT; Huang Y; Mishler K; Roerig SC; O'Donnell JM
Psychopharmacology (Berl); 2005 Oct; 182(1):104-15. PubMed ID: 16010541
[TBL] [Abstract][Full Text] [Related]
4. Effects of the novel PDE4 inhibitors MEM1018 and MEM1091 on memory in the radial-arm maze and inhibitory avoidance tests in rats.
Zhang HT; Huang Y; Suvarna NU; Deng C; Crissman AM; Hopper AT; De Vivo M; Rose GM; O'Donnell JM
Psychopharmacology (Berl); 2005 May; 179(3):613-9. PubMed ID: 15672274
[TBL] [Abstract][Full Text] [Related]
5. Behavioral effects of family-selective inhibitors of cyclic nucleotide phosphodiesterases.
O'Donnell JM; Frith S
Pharmacol Biochem Behav; 1999 May; 63(1):185-92. PubMed ID: 10340540
[TBL] [Abstract][Full Text] [Related]
6. Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.
Martin C; Göggel R; Dal Piaz V; Vergelli C; Giovannoni P; Ernst M; Uhlig S
Naunyn Schmiedebergs Arch Pharmacol; 2002 Apr; 365(4):284-9. PubMed ID: 11919652
[TBL] [Abstract][Full Text] [Related]
7. Antidepressant-induced increase in high-affinity rolipram binding sites in rat brain: dependence on noradrenergic and serotonergic function.
Zhao Y; Zhang HT; O'Donnell JM
J Pharmacol Exp Ther; 2003 Oct; 307(1):246-53. PubMed ID: 12954819
[TBL] [Abstract][Full Text] [Related]
8. Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme.
Zhang HT; Huang Y; Jin SL; Frith SA; Suvarna N; Conti M; O'Donnell JM
Neuropsychopharmacology; 2002 Oct; 27(4):587-95. PubMed ID: 12377395
[TBL] [Abstract][Full Text] [Related]
9. Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats.
Makhay MM; Houslay MD; O'Donnell JM
Psychopharmacology (Berl); 2001 Nov; 158(3):297-304. PubMed ID: 11713620
[TBL] [Abstract][Full Text] [Related]
10. Effects of repeated treatment with phosphodiesterase-4 inhibitors on cAMP signaling, hippocampal cell proliferation, and behavior in the forced-swim test.
Xiao L; O'Callaghan JP; O'Donnell JM
J Pharmacol Exp Ther; 2011 Aug; 338(2):641-7. PubMed ID: 21566211
[TBL] [Abstract][Full Text] [Related]
11. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases.
Souness JE; Rao S
Cell Signal; 1997; 9(3-4):227-36. PubMed ID: 9218122
[TBL] [Abstract][Full Text] [Related]
12. Effects of rolipram, a phosphodiesterase 4 inhibitor, in combination with imipramine on depressive behavior, CRE-binding activity and BDNF level in learned helplessness rats.
Itoh T; Tokumura M; Abe K
Eur J Pharmacol; 2004 Sep; 498(1-3):135-42. PubMed ID: 15363987
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo.
Cooper N; Teixeira MM; Warneck J; Miotla JM; Wills RE; Macari DM; Gristwood RW; Hellewell PG
Br J Pharmacol; 1999 Apr; 126(8):1863-71. PubMed ID: 10372831
[TBL] [Abstract][Full Text] [Related]
15. Behavioural effects of selective PDE4 inhibitors in relation to inhibition of catalytic activity and competition for [3H]rolipram binding.
Kapui Z; Bence J; Boronkay E; Mikus E; Urbán Szabó K; Baranyi A; Arányi P
Neurobiology (Bp); 1999; 7(1):71-3. PubMed ID: 10746252
[No Abstract] [Full Text] [Related]
16. Regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4).
Thompson WJ; Ashikaga T; Kelly JJ; Liu L; Zhu B; Vemavarapu L; Strada SJ
Biochem Pharmacol; 2002 Feb; 63(4):797-807. PubMed ID: 11992650
[TBL] [Abstract][Full Text] [Related]
17. Administration of a cAMP phosphodiesterase 4 inhibitor enhances antidepressant-induction of BDNF mRNA in rat hippocampus.
Fujimaki K; Morinobu S; Duman RS
Neuropsychopharmacology; 2000 Jan; 22(1):42-51. PubMed ID: 10633490
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus.
Zhang HT; Zhao Y; Huang Y; Dorairaj NR; Chandler LJ; O'Donnell JM
Neuropsychopharmacology; 2004 Aug; 29(8):1432-9. PubMed ID: 15114341
[TBL] [Abstract][Full Text] [Related]
19. In vivo and in vitro measurement of brain phosphodiesterase 4 in rats after antidepressant administration.
Fujita M; Imaizumi M; D'Sa C; Zoghbi SS; Crescenzo MS; Hong J; Musachio JL; Gee AD; Seidel J; Green MV; Pike VW; Duman RS; Innis RB
Synapse; 2007 Feb; 61(2):78-86. PubMed ID: 17117418
[TBL] [Abstract][Full Text] [Related]
20. CDP840: a novel inhibitor of PDE-4.
Perry MJ; O'Connell J; Walker C; Crabbe T; Baldock D; Russell A; Lumb S; Huang Z; Howat D; Allen R; Merriman M; Walls J; Daniel T; Hughes B; Laliberte F; Higgs GA; Owens RJ
Cell Biochem Biophys; 1998; 29(1-2):113-32. PubMed ID: 9631241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
